Evidence map›Paper›PMID 35430229›Full record

ArticleAmerican journal of obstetrics and gynecology2022

Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.

Yannic C Bartsch, Caroline Atyeo, Jaewon Kang, Yongfei Cai, Bing Chen, Kathryn J Gray, Andrea G Edlow, Galit Alter

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yannic C BartschRagon Institute of MGH, MIT and Harvard, Cambridge, MA.
Caroline AtyeoRagon Institute of MGH, MIT and Harvard, Cambridge, MA.
Jaewon KangRagon Institute of MGH, MIT and Harvard, Cambridge, MA.
Yongfei CaiDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Bing ChenDivision of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Kathryn J GrayDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Andrea G EdlowDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA. Electronic address: GALTER@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USBoston Children's Hospital · USBrigham and Women's Hospital · USHarvard University · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
Structure of the full-length spike protein of SARS-CoV-2 in the context of membraneR01AI147884 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CHEN, BING · 2020 to 2024
$3.4M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
Sex Differences in Fetal Brain-Placental Immune Programming in Maternal ObesityR01HD100022 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI EDLOW, ANDREA GOLDBERG · 2019 to 2021
$2.0M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
Signatures of dysfunctional mitochondrial fatty acid oxidation that predispose to early-onset preeclampsiaK08HL146963 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GRAY, KATHRYN JOHNSON · 2019 to 2023
$940k
NCI NIH HHS U01 CA260476NHLBI NIH HHS K08 HL146963NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R01 AI147884NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NICHD NIH HHS R01 HD100022
6 · The paper itself

Abstract

backgroundSARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among pregnant women. Just as coordinated messaging from the Centers for Disease Control and Prevention and leading obstetrics organizations began to increase vaccine confidence in this vulnerable group, the evolution of SARS-CoV-2 variants of concerns, including the Omicron variant, raised new concerns about vaccine efficacy because of their ability to escape vaccine-induced neutralizing antibodies. Early data point to a milder disease course following infection with the Omicron variant in vaccinated individuals. Thus, these data suggest that alternate vaccine-induced immunity beyond neutralization may continue to attenuate Omicron variant-induced disease, such as Fc-mediated antibody activity.

objectiveThis study aimed to test whether vaccine-induced antibodies raised during pregnancy continue to bind to and leverage Fc receptors to protect against variants of concern including the Omicron variant. STUDY

designThe receptor binding domain or whole spike-specific antibody isotype binding titers and Fc gamma receptor binding directed toward variants of concern, including the Omicron variant, were analyzed in pregnant women after receiving the full dose regimen of either the Pfizer/BioNTech BNT62b2 (n=10) or Moderna mRNA-1273 (n=10) vaccination using a multiplexing Luminex assay.

resultsReduced isotype recognition of the Omicron receptor binding domain was observed following administration of either vaccine with relatively preserved, albeit reduced, recognition of the whole Omicron spike by immunoglobulin M and G antibodies. Despite the near complete loss of Fc receptor binding to the Omicron receptor binding domain, Fc receptor binding to the Omicron spike was more variable but largely preserved.

conclusionReduced binding titers to the Omicron receptor binding domain aligns with the observed loss of neutralizing activity. Despite the loss of neutralization, preserved, albeit reduced, Omicron spike recognition and Fc receptor binding potentially continue to attenuate disease severity in pregnant women.

Indexed as

COVID-19Pregnancy Complications, InfectiousVaccinesAntibodies, ViralCOVID-19 VaccinesFemaleHumansMembrane GlycoproteinsPregnancyReceptors, FcRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationViral Envelope ProteinsAntibodies, ViralCOVID-19 VaccinesMembrane GlycoproteinsReceptors, FcRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2VaccinesViral Envelope ProteinsantibodiesFcγ receptormRNA vaccineOmicron variantpregnancySARS-CoV-2variants of concern

Identifiers

PMID35430229
PMCPMC9008975
OpenAlexW4225934684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.